Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term satavaptan safety extension in cirrhotic ascites
2006-006521-30Phase 3Terminated
- Sponsor
- Sanofi
- Start
- Jun 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ascites and Cirrhosis comparing Satavaptan with Placebo (2 arms). Primary endpoint: Long-term safety. Started Jun 2007; status: terminated.
02
Drugs
satavaptan
03
Conditions
ascitesCirrhosis
Beyond the preview
Go deeper on 2006-006521-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006521-30.